This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Alibhai, S. M.H. Articles by Krahn, M. D. Search for Related Content PubMed PubMed Citation Articles by Alibhai, S. M.H. Articles by Krahn, M. D.

Do Older Men Benefit From Curative Therapy of Localized Prostate Cancer?

Shabbir M.H. Alibhai, Gary Naglie, Robert Nam, John Trachtenberg, Murray D. Krahn

From the Division of General Internal Medicine & Clinical Epidemiology, University Health Network; Geriatric Program, Toronto Rehabilitation Institute; and Departments of Medicine, Health Policy, Management and Evaluation, and Surgery, University of Toronto, Toronto, Canada.

Address reprint requests to S.M.H. Alibhai, MD, University Health Network, Room ENG-233, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4; e-mail: shabbir.alibhai{at}uhn.on.ca.

Purpose: Prior decision-analytic models are based on outdated or suboptimal efficacy, patient preference, and comorbidity data. We estimated life expectancy (LE) and quality-adjusted life expectancy (QALE) associated with available treatments for localized prostate cancer in men aged 65 years, adjusting for Gleason score, patient preferences, and comorbidity.

Methods: We evaluated three treatments, using a decision-analytic Markov model: radical prostatectomy (RP), external beam radiotherapy (EBRT), and watchful waiting (WW). Rates of treatment complications and pretreatment incontinence and impotence were derived from published studies. We estimated treatment efficacy using three data sources: cancer registry cohort data, pooled case series, and modern radiotherapy studies. Utilities were obtained from 141 prostate cancer patients and from published studies.

Results: For men with well-differentiated tumors and few comorbidities, potentially curative therapy (RP or EBRT) prolonged LE up to age 75 years but did not improve QALE at any age. For moderately differentiated cancers, potentially curative therapy resulted in LE and QALE gains up to age 75 years. For poorly differentiated disease, potentially curative therapy resulted in LE and QALE gains up to age 80 years. Benefits of potentially curative therapy were restricted to men with no worse than mild comorbidity. When cohort and pooled case series data were used, RP was preferred over EBRT in all groups but was comparable to modern radiotherapy.

Conclusion: Potentially curative therapy results in significantly improved LE and QALE for older men with few comorbidities and moderately or poorly differentiated localized prostate cancer. Age should not be a barrier to treatment in this group.

Supported in part by the Department of Medicine, University of Toronto; the Queen Elizabeth Hospital Research Foundation, Toronto; and the Toronto Rehabilitation Institute (S.M.H.A.), by the Mary Trimmer Chair in Geriatric Medicine Research at the University of Toronto (G.N.), and by an Investigator Award (M.D.K.) from the Canadian Institutes for Health Research.

This article has been cited by other articles:

				R. Mohan Family Physicians Could Help in Predicting Life Expectancy Without Prostate Cancer J. Clin. Oncol., February 1, 2008; 26(4): 690 - 691. [Full Text] [PDF]

				F. Shimizu, A. Igarashi, T. Fukuda, Y. Kawachi, S. Minowada, Y. Ohashi, and M. Fujime Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era Jpn. J. Clin. Oncol., October 22, 2007; (2007) hym105v1. [Abstract] [Full Text] [PDF]

				H. B. Shim, S. E. Lee, H. K. Park, and J. H. Ku Histological Diagnosis of Prostate Cancer in Korean Men Aged 70 79 Years Jpn. J. Clin. Oncol., October 3, 2007; (2007) hym093v1. [Abstract] [Full Text] [PDF]

				K. E. Bremner, C. A. K. Y. Chong, G. Tomlinson, S. M. H. Alibhai, and M. D. Krahn A Review and Meta-Analysis of Prostate Cancer Utilities Med Decis Making, May 1, 2007; 27(3): 288 - 298. [Abstract] [PDF]

				D. C. Miller, S. B. Gruber, B. K. Hollenbeck, J. E. Montie, and J. T. Wei Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst, August 16, 2006; 98(16): 1134 - 1141. [Abstract] [Full Text] [PDF]

				R. M. Hoffman Viewpoint: limiting prostate cancer screening. Ann Intern Med, March 21, 2006; 144(6): 438 - 440. [Abstract] [Full Text] [PDF]

				S. M. H. Alibhai, M. Leach, G. Tomlinson, M. D. Krahn, N. Fleshner, E. Holowaty, and G. Naglie 30-Day Mortality and Major Complications after Radical Prostatectomy: Influence of Age and Comorbidity J Natl Cancer Inst, October 19, 2005; 97(20): 1525 - 1532. [Abstract] [Full Text] [PDF]

				M. R. Cooperberg, D. P. Lubeck, M. V. Meng, S. S. Mehta, and P. R. Carroll The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management J. Clin. Oncol., June 1, 2004; 22(11): 2141 - 2149. [Abstract] [Full Text] [PDF]